再燃、再感染还是复发?评估氯喹治疗间日疟疗效的更严格框架
研究在柬埔寨东北部纳入40例间日疟患者,采用氯喹30 mg/kg治疗并随访2个月,通过频繁镜检、分子检测、基因分型和药物浓度测定,并将患者移至无传播区防止再感染。结果显示所有患者第3天寄生虫清除,24例出现复发感染且氯喹浓度均低于治疗水平,基因分析提示三分之二复发为异源复发,未见氯喹耐药证据。作者认为间日疟抗疟药耐药可能被高估,现行临床药物研究指南需修订。
要点
- 40例间日疟患者接受氯喹30 mg/kg治疗,第3天全部寄生虫清除。
- 24例出现复发感染,其氯喹血药浓度均低于治疗水平,二次氯喹治疗有效。
- 基因分型显示8例复发中6例为异源复发,未见氯喹耐药证据。
核心结论
- 未观察到氯喹耐药证据,间日疟抗疟药耐药可能被高估,现行间日疟临床药物研究指南需修订。
研究设计与样本
- 在柬埔寨东北部纳入40例间日疟患者,既往该地区报告治疗失败率>17%。
- 患者接受氯喹30 mg/kg治疗并随访2个月,频繁临床检查及毛细血管采血进行镜检、分子检测、基因分型和药物浓度测定。
- 通过将患者移至无传播区防止再感染。
主要发现
- 所有患者第3天寄生虫被清除。
- 多克隆感染中所有克隆以相同速率清除,提示对氯喹敏感性相同。
- 24/40例出现复发感染,其氯喹血药浓度均低于治疗水平,二次氯喹治疗有效清除。
- 基因分型(128 SNPs条码)和全基因组测序(Illumina)显示,8例复发寄生虫中6例(三分之二)为异源复发,其中50%来自同胞/重组克隆。
关键数值与推荐
- 氯喹剂量为30 mg/kg。
- 随访时间为2个月。
- 既往该地区报告治疗失败率>17%。
临床怎么用
- 作者认为间日疟抗疟药耐药可能被高估,现行间日疟临床药物研究指南需修订。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient outcomes. METHODS: We enrolled 40 patients with P. vivax malaria in northeastern Cambodia, where >17% treatment failures were previously reported. Patients were treated with CQ (30 mg/kg) and followed for 2 months, with frequent clinical examination and capillary blood sample collection for microscopy, molecular parasite detection and genotyping, and drug concentration measurements. Reinfections were prevented by relocating patients to a transmission-free area. RESULTS: P. vivax parasites were eliminated in all patients by day 3. Genomic analyses revealed that all clones in polyclonal infections were cleared at the same rate, indicating their equal susceptibility to CQ. CQ blood concentrations were below the therapeutic level in all recurrent infections (24 of 40 patients), which were efficiently cleared by a second course of CQ treatment. Genotyping (128 SNPs barcode) and sequences of entire parasite genome (Whole-Genome Sequencing, Illumina) indicated that two thirds (6 of 8) of the recurrent parasites resulted from heterologous relapses whose 50% are from by sibling/recombinant clones. CONCLUSIONS: No evidence of CQ resistance was observed. Our data suggest that P. vivax antimalarial drug resistance is likely overestimated and that the current guidelines for clinical drug studies of P. vivax malaria need to be revised.
引用
- Popovici J, Pierce-Friedrich L, Kim S, et al. Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. J Infect Dis. 2019. PMID: 30102351. doi:10.1093/infdis/jiy484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。